Checking How Consistent Glucose Sensors Are in Children With Cystic Fibrosis
Tests how consistent continuous glucose monitoring readings are in children with cystic fibrosis.
Plain-language title generated from the registry record
Registry title: Reproducibility of Continuous Glucose Monitoring (CGM) in the Assessment of Glucose Metabolism Disorders in Children With Cystic Fibrosis
Key facts
- Where
- Bron, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 10 and 17 years old?
Source: NCT07851831, who can take part
Where in France
- Hôpital Femme Mère Enfant (HFME)Bron, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospices Civils de Lyon
- Trial code
- NCT07851831
- Record updated
- 1 October 2026
- Original description
Glucose metabolism disorders in cystic fibrosis (CF-GMD) are common and have a negative clinical impact. Screening currently relies on the oral glucose tolerance test (OGTT); however, this procedure is burdensome and complex for both patients and healthcare providers. Continuous glucose monitoring (CGM) is increasingly used in CF centers for CF-GMD screening, either alone or alongside the OGTT. While long-term (one-year) OGTT reproducibility is known to be poor, the short- and medium-term reproducibility of CGM remains unknown. This examination is poised to become a major tool in CF-GMD investigation, upon which critical therapeutic decisions could be based. The primary objective of this project is to evaluate the short-term variability of CGM data.Read full original descriptionShow less
Reproducibility of Continuous Glucose Monitoring (CGM) in the Assessment of Glucose Metabolism Disorders in Children With Cystic Fibrosis
Glucose metabolism disorders in cystic fibrosis (CF-GMD) are common and have a negative clinical impact. Screening currently relies on the oral glucose tolerance test (OGTT); however, this procedure is burdensome and complex for both patients and healthcare providers. Continuous glucose monitoring (CGM) is increasingly used in CF centers for CF-GMD screening, either alone or alongside the OGTT. While long-term (one-year) OGTT reproducibility is known to be poor, the short- and medium-term reproducibility of CGM remains unknown. This examination is poised to become a major tool in CF-GMD investigation, upon which critical therapeutic decisions could be based. The primary objective of this project is to evaluate the short-term variability of CGM data.
Inclusion: Patients aged 10 to 17 years; Diagnosed with cystic fibrosis (CF); Managed by the pediatric CF care center (CRCM) of the Groupement Hospitalier Est; Patients presenting with one of the following three stages are included: normal glucose tolerance with or without indeterminate glucose tolerance (INDET), impaired fasting glucose (IFG), and impaired glucose tolerance (IGT).
Exclusion: Patients presenting with a pulmonary exacerbation and currently receiving antibiotic therapy; Patients with treated or untreated diabetes; Persons undergoing psychiatric care; Patients participating in another clinical trial that could interfere, in the investigator's judgment, with the study findings; Refusal of the patient and/or the legal guardian(s) to participate in the study; Pregnant, parturient, or breastfeeding women; Persons deprived of liberty by a judicial or administrative decision; Persons admitted to a healthcare or social institution for purposes other than research; Persons not affiliated with a social security scheme or beneficiaries of a similar scheme.